[go: up one dir, main page]

IN2015DN02829A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02829A
IN2015DN02829A IN2829DEN2015A IN2015DN02829A IN 2015DN02829 A IN2015DN02829 A IN 2015DN02829A IN 2829DEN2015 A IN2829DEN2015 A IN 2829DEN2015A IN 2015DN02829 A IN2015DN02829 A IN 2015DN02829A
Authority
IN
India
Prior art keywords
compound
formula
effective amount
therapeutically effective
present
Prior art date
Application number
Inventor
Niels; Svenstrup
Klaus Baek; Si-Monsen
Lars Kyhn; Rasmussen
Karsten; Juhl
Morten; Langgard
Kate; Wen
Yazhou; Wang
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IN2015DN02829A publication Critical patent/IN2015DN02829A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention is directed to compounds , which are PDE9 enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula (I). The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I). The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula (I).
IN2829DEN2015 2011-10-10 2012-10-09 IN2015DN02829A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011001692 2011-10-10
PCT/EP2012/069936 WO2013053690A1 (en) 2011-10-10 2012-10-09 Pde9i with imidazo pyrazinone backbone

Publications (1)

Publication Number Publication Date
IN2015DN02829A true IN2015DN02829A (en) 2015-09-11

Family

ID=47019007

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2829DEN2015 IN2015DN02829A (en) 2011-10-10 2012-10-09

Country Status (15)

Country Link
US (2) US9643970B2 (en)
EP (2) EP3121178B1 (en)
JP (1) JP2015531401A (en)
CN (2) CN106905324B (en)
AU (2) AU2012323085B2 (en)
BR (1) BR112015007731B1 (en)
CA (1) CA2886885C (en)
HK (1) HK1211023A1 (en)
IL (2) IL237836A (en)
IN (1) IN2015DN02829A (en)
MA (1) MA37958B1 (en)
MX (2) MX381326B (en)
SG (1) SG11201502728WA (en)
TN (1) TN2015000100A1 (en)
WO (1) WO2013053690A1 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3121178B1 (en) * 2011-10-10 2018-09-19 H. Lundbeck A/S 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
SMT201900620T1 (en) 2014-02-13 2020-01-14 Incyte Corp Cyclopropylamines as lsd1 inhibitors
PL3105218T3 (en) 2014-02-13 2020-03-31 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TW201629064A (en) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 Triazolopyrainones as PDE1 inhibitors
ES2757948T3 (en) 2015-04-03 2020-04-30 Incyte Corp Heterocyclic compounds as LSD1 inhibitors
JO3627B1 (en) * 2015-04-30 2020-08-27 H Lundbeck As Imidazopyrazinones as PDE1 inhibitors
SI3865484T1 (en) * 2015-07-07 2024-05-31 H. Lundbeck A/S Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases
TW201717948A (en) * 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines
AU2016306555B2 (en) 2015-08-12 2021-01-28 Incyte Holdings Corporation Salts of an LSD1 inhibitor
MX376639B (en) * 2015-11-09 2025-03-07 Astrazeneca Ab Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
TWI729109B (en) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 1,5-DIHYDRO-4H-PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND 1,5-DIHYDRO-4H-PYRAZOLO[4,3-c]PYRIDIN-4-ONES AS PDE1 INHIBITORS
IL262488B (en) 2016-04-22 2022-08-01 Incyte Corp Formulations of an lsd1 inhibitor
MX2018016127A (en) * 2016-07-06 2019-05-30 Imara Inc Pde9 inhibitors for treatment of peripheral diseases.
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
AU2017350473A1 (en) 2016-10-28 2019-04-18 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
CA3041595A1 (en) * 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
CA3045745A1 (en) * 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazin as oga inhibitors
RS65143B1 (en) * 2017-05-26 2024-02-29 Cardurion Pharmaceuticals Inc Methods of making and using pde9 inhibitors
KR20200013758A (en) 2017-06-08 2020-02-07 머크 샤프 앤드 돔 코포레이션 Pyrazolopyrimidine PDE9 Inhibitor
WO2019101511A1 (en) 2017-11-23 2019-05-31 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
KR20210014662A (en) 2018-05-25 2021-02-09 이마라 인크. 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1, 5-a]Pyrazin-8-one monohydrate and crystalline form
JP2021527662A (en) * 2018-06-20 2021-10-14 ヤンセン ファーマシューティカ エヌ．ベー． OGA inhibitor compound
CN112996512B (en) 2018-08-31 2025-01-03 卡都瑞恩医药公司 PDE9 inhibitors for the treatment of sickle cell disease
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
WO2020206336A1 (en) * 2019-04-05 2020-10-08 Imara Inc. Pde9 inhibitors for treating sickle cell disease
CN114072151A (en) * 2019-05-07 2022-02-18 伊马拉公司 PDE9 inhibitors for the treatment of thalassemia
WO2022036111A1 (en) * 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135462A0 (en) 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
BR0007613A (en) 1999-01-20 2001-10-30 Dresden Arzneimittel Imidazo [1,5-a] -pyrido [3,2-e] -pyrazinones application as medicine
IL161155A0 (en) 2001-11-02 2004-08-31 Pfizer Prod Inc Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
HN2002000317A (en) * 2001-11-02 2003-05-21 Pfizer PDE9 INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISORDERS
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005041972A1 (en) 2003-10-31 2005-05-12 Pfizer Products Inc. Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
CA2620223A1 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2008029589A1 (en) 2006-09-08 2008-03-13 Tokuyama Corporation Method and equipment for producing group-iii nitride
KR20090097918A (en) * 2006-12-13 2009-09-16 아스카 세이야쿠 가부시키가이샤 Treatment of urinary tract diseases
ES2536906T3 (en) 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Quinoxaline derivative
UA94660C2 (en) * 2007-05-11 2011-05-25 Пфайзер Инк. Amino-heterocyclic compounds
DE102007032349A1 (en) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo, pyrazolopyrazines and imidazotriazines and their use
TWI404721B (en) 2009-01-26 2013-08-11 Pfizer Amino-heterocyclic compounds
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
ES2610360T3 (en) * 2010-09-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Imidazotriazinone Compounds
KR101943680B1 (en) 2011-10-07 2019-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 Pyrazoloquinoline derivative
EP3121178B1 (en) * 2011-10-10 2018-09-19 H. Lundbeck A/S 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
WO2013142269A1 (en) 2012-03-19 2013-09-26 Envivo Pharmaceuticals, Inc. Imidazotriazinone compounds

Also Published As

Publication number Publication date
MX2019014982A (en) 2020-02-24
AU2017201873B2 (en) 2018-03-29
AU2012323085A1 (en) 2015-04-02
CA2886885C (en) 2019-07-16
EP2906562A1 (en) 2015-08-19
SG11201502728WA (en) 2015-05-28
BR112015007731B1 (en) 2022-05-31
EP2906562B1 (en) 2016-10-05
CN106905324B (en) 2018-09-25
IL253448A0 (en) 2017-09-28
EP3121178A1 (en) 2017-01-25
WO2013053690A1 (en) 2013-04-18
US20170173018A1 (en) 2017-06-22
MA37958A1 (en) 2017-11-30
US20150274736A1 (en) 2015-10-01
MX381326B (en) 2025-03-12
MA37958B1 (en) 2018-10-31
HK1211023A1 (en) 2016-05-13
AU2017201873C1 (en) 2018-08-02
EP3121178B1 (en) 2018-09-19
TN2015000100A1 (en) 2016-06-29
US9993477B2 (en) 2018-06-12
CA2886885A1 (en) 2013-04-18
CN104703987B (en) 2017-05-03
BR112015007731A2 (en) 2017-07-04
CN104703987A (en) 2015-06-10
MX2015004422A (en) 2015-10-15
CN106905324A (en) 2017-06-30
JP2015531401A (en) 2015-11-02
AU2017201873A1 (en) 2017-04-06
MX370433B (en) 2019-12-13
US9643970B2 (en) 2017-05-09
AU2012323085B2 (en) 2017-03-09
IL237836A (en) 2017-07-31

Similar Documents

Publication Publication Date Title
IN2015DN02829A (en)
PH12014501695B1 (en) Pde9 inhibitors with imidazo triazinone backbone
TN2012000287A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MY152949A (en) Novel phenylimidazole derivatives as pde10a enzyme inhibitors
PH12013500968A1 (en) Imidazole derivatives as pde10a enzyme inhibitors
UA102693C2 (en) Phenylimidazole derivatives as pde10a enzyme inhibitors
TN2012000271A1 (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
PH12012501202A1 (en) Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
MX336915B (en) Imidazole derivatives as pde10a enzyme inhibitors.
TN2013000200A1 (en) Imidazole derivatives as pde 10a enzyme inhibitors
TN2014000288A1 (en) Pde9 inhibitors with imidazo triazinone backbone
CY1116689T1 (en) Imidazole derivatives as inhibitors of the PDE10A enzyme